Helsinn Holding SA, a privately-owned pharmaceutical company, is to establish a centre of excellence in R&D of oral solid dosage at its existing site in Dublin.
The €13 million project, which is backed by the Irish government, is expected to create 10 research positions.
Helsinn’s core business is the in-licensing of late-stage pharmaceutical compounds in therapeutic niche areas for development and subsequent commercial manufacture and distribution. The company is primarily active in oncology supportive care, anti-inflammatory and gastrointestinal treatments. The investment is part of Helsinn’s strategic decision to strengthen its in-house development capability.
Helsinn’s Irish operation was established in 1990, when it acquired Birex Pharmaceuticals in Dublin. To date the Swiss company has invested over €55 million in Ireland and now employs 210 people.
Receive the Funding Newswire each Tuesday, our Policy Bulletin each Thursday, and news about bridging Europe’s east-west innovation gap twice a month in The Widening. 
A unique international forum for public research organisations and companies to connect their external engagement with strategic interests around their R&D system.
